DIA Biosimilars 2013

Sandoz

DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

More... »

Cenduit: Now with Patient Reminders

Novartis to acquire Fougera Pharmaceuticals

Friday, May 4, 2012 08:02 AM

Switzerland-based Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals of Melville, N.Y., for $1.5 billion in cash.

More... »

CRF Health – eCOA Forum

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

FDA approves generic olanzapine injection

Thursday, October 27, 2011 10:40 AM

The FDA has approved INNOPHARMA’s Abbreviated New Drug Application (ANDA) for olanzapine injection (the generic equivalent of ZyprexaR injection).

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs